CIA BRASILEIRA DE DIS- ADR (CBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CBD - US20440T3005 - ADR
0.445 USD
-0.01 (-3.05%)
0.4357 USD
-0.01 (-2.09%)
CBD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 38 industry peers in the Consumer Staples Distribution & Retail industry. CBD may be in some trouble as it scores bad on both profitability and health. CBD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CBD had negative earnings in the past year.
CBD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CBD reported negative net income in multiple years.
Of the past 5 years CBD 4 years had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -10.30%, CBD is not doing good in the industry: 78.05% of the companies in the same industry are doing better.
CBD has a Return On Equity of -48.12%. This is amonst the worse of the industry: CBD underperforms 80.49% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.48%, CBD is doing worse than 70.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROIC | 0.48% |
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CBD has a Operating Margin of 0.50%. This is in the lower half of the industry: CBD underperforms 68.29% of its industry peers.
CBD's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 25.02%, CBD is in the better half of the industry, outperforming 63.41% of the companies in the same industry.
CBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% |
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CBD is destroying value.
The number of shares outstanding for CBD remains at a similar level compared to 1 year ago.
The debt/assets ratio for CBD is higher compared to a year ago.
2.2 Solvency
CBD has an Altman-Z score of 1.07. This is a bad value and indicates that CBD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.07, CBD is not doing good in the industry: 73.17% of the companies in the same industry are doing better.
A Debt/Equity ratio of 1.72 is on the high side and indicates that CBD has dependencies on debt financing.
With a Debt to Equity ratio value of 1.72, CBD is not doing good in the industry: 82.93% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.07 |
ROIC/WACC0.09
WACC5.48%
2.3 Liquidity
CBD has a Current Ratio of 1.21. This is a normal value and indicates that CBD is financially healthy and should not expect problems in meeting its short term obligations.
CBD has a Current ratio (1.21) which is in line with its industry peers.
A Quick Ratio of 0.89 indicates that CBD may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.89, CBD is in the better half of the industry, outperforming 70.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for CBD have decreased strongly by -1171.43% in the last year.
CBD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.86%.
Measured over the past years, CBD shows a very negative growth in Revenue. The Revenue has been decreasing by -17.17% on average per year.
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
3.2 Future
Based on estimates for the next years, CBD will show a very strong growth in Earnings Per Share. The EPS will grow by 24.83% on average per year.
CBD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.97% yearly.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CBD is cheaper than 85.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CBD's earnings are expected to grow with 24.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 13.41%, CBD is a good candidate for dividend investing.
The stock price of CBD dropped by -47.63% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CBD's Dividend Yield is rather good when compared to the industry average which is at 0.78. CBD pays more dividend than 100.00% of the companies in the same industry.
CBD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
5.2 History
The dividend of CBD decreases each year by -24.04%.
CBD has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
CBD has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
0.445
-0.01 (-3.05%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)
Earnings (Next)
Inst Owners0.12%
Inst Owner Change-16.19%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap218.06M
Revenue(TTM)19.25B
Net Income(TTM)-2.27B
Analysts50
Price Target1.53 (243.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
Yearly Dividend0.41
Dividend Growth(5Y)-24.04%
DP-4.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-273.86%
Min EPS beat(2)-455.83%
Max EPS beat(2)-91.89%
EPS beat(4)0
Avg EPS beat(4)-228.76%
Min EPS beat(4)-455.83%
Max EPS beat(4)-25.58%
EPS beat(8)0
Avg EPS beat(8)-362.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-4.34%
Max Revenue beat(2)-3.47%
Revenue beat(4)0
Avg Revenue beat(4)-27.12%
Min Revenue beat(4)-59.79%
Max Revenue beat(4)-3.47%
Revenue beat(8)2
Avg Revenue beat(8)-9.38%
Revenue beat(12)3
Avg Revenue beat(12)-9.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.66%
PT rev (3m)-10.73%
EPS NQ rev (1m)54.81%
EPS NQ rev (3m)58.85%
EPS NY rev (1m)49.53%
EPS NY rev (3m)46.14%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.06 | ||
| P/FCF | N/A | ||
| P/OCF | 1.99 | ||
| P/B | 0.24 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | 5 |
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.22
OCFY50.28%
SpS7.65
BVpS1.88
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROCE | 0.61% | ||
| ROIC | 0.48% | ||
| ROICexc | 0.63% | ||
| ROICexgc | 0.76% | ||
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% | ||
| FCFM | N/A |
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-58.82%
ROICexgc growth 5Y-42.48%
ROICexc growth 3Y-57.55%
ROICexc growth 5Y-42.78%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
F-Score2
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.59 | ||
| Cap/Depr | 103.08% | ||
| Cap/Sales | 6.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.07 |
F-Score2
WACC5.48%
ROIC/WACC0.09
Cap/Depr(3y)82.81%
Cap/Depr(5y)104.8%
Cap/Sales(3y)7.75%
Cap/Sales(5y)7.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
EBIT growth 1Y-87.1%
EBIT growth 3Y-67.17%
EBIT growth 5Y-48.29%
EBIT Next Year586.28%
EBIT Next 3Y102.85%
EBIT Next 5Y76.66%
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y360.65%
OCF growth 3Y-50.85%
OCF growth 5Y-33.31%
CIA BRASILEIRA DE DIS- ADR / CBD FAQ
Can you provide the ChartMill fundamental rating for CIA BRASILEIRA DE DIS- ADR?
ChartMill assigns a fundamental rating of 2 / 10 to CBD.
What is the valuation status for CBD stock?
ChartMill assigns a valuation rating of 1 / 10 to CIA BRASILEIRA DE DIS- ADR (CBD). This can be considered as Overvalued.
Can you provide the profitability details for CIA BRASILEIRA DE DIS- ADR?
CIA BRASILEIRA DE DIS- ADR (CBD) has a profitability rating of 2 / 10.
Can you provide the financial health for CBD stock?
The financial health rating of CIA BRASILEIRA DE DIS- ADR (CBD) is 1 / 10.